All methods of immunotherapy could be used in advanced NSCLC patients after excluding the presence of at least basic genetic abnormalities in the EGFR, ALK, and ROS1 genes since the low effectiveness of immunotherapy in such patients has been proven. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.